ANTI-INFLAMMATORY EFFECT OF ANTI-TNF-ALPHA siRNA CATIONIC PHOSPHOROUS DENDRIMERS NANOCOMPLEXES ADMINISTERED INTRANASALLY IN A MURINE ACUTE LUNG INJURY MODEL
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
ANTI-INFLAMMATORY EFFECT OF ANTI-TNF-ALPHA siRNA CATIONIC PHOSPHOROUS DENDRIMERS NANOCOMPLEXES ADMINISTERED INTRANASALLY IN A MURINE ACUTE LUNG INJURY MODEL. / Bohr, Adam; Tsapis, Nicolas; Andreana, Ilaria ; Chamarat, Anais; Foged, Camilla; Delomenie, Claudine ; Noiray, Magali ; El Brahmi, Nabil ; Majoral, Jean-Pierre; Mignani, Serge ; Fattal, Elias .
In: Biomacromolecules, Vol. 18, No. 8, 21.06.2017, p. 2379–2388.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - ANTI-INFLAMMATORY EFFECT OF ANTI-TNF-ALPHA siRNA CATIONIC PHOSPHOROUS DENDRIMERS NANOCOMPLEXES ADMINISTERED INTRANASALLY IN A MURINE ACUTE LUNG INJURY MODEL
AU - Bohr, Adam
AU - Tsapis, Nicolas
AU - Andreana, Ilaria
AU - Chamarat, Anais
AU - Foged, Camilla
AU - Delomenie, Claudine
AU - Noiray, Magali
AU - El Brahmi, Nabil
AU - Majoral, Jean-Pierre
AU - Mignani, Serge
AU - Fattal, Elias
PY - 2017/6/21
Y1 - 2017/6/21
N2 - Inflammation is an essential component of many lung diseases, including asthma, chronic obstructive pulmonary disease (COPD) or acute lung injury. Our purpose was to design efficient carriers for lung delivery of small interfering RNA (siRNA) targeting tumor necrosis factor (TNF)alphain an acute lung injury model. To achieve this goal, two different types of phosphorus-based dendrimers with either pyrrolidinium or morpholinium as terminal protonated amino groups were selected for their better biocompatibility compared to other dendrimers. Dendriplexes containing pyrrolidinium surface groups demonstrated a stronger siRNA complexation, a higher cellular uptake and enhanced in vitro silencing efficiency of TNF-alpha in the lipopolysaccharide (LPS)-activated mouse macrophage cell line RAW264.7, compared to morpholinium-containing dendriplexes. The better performance of the pyrrolidium dendriplexes was attributed to their higher pKa value leading to a stronger siRNA complexation and improved protection against enzymatic degradation resulting in a higher cellular uptake. The superior silencing effect of the pyrrolidinium dendriplexes, compared to non-complexed siRNA, was confirmed in vivo in an LPS-induced murine model of short term acute lung injury upon lung delivery via nasal administration. These data suggest that phosphorous dendriplexes have a strong potential in lung delivery of siRNA for treating inflammatory lung diseases.
AB - Inflammation is an essential component of many lung diseases, including asthma, chronic obstructive pulmonary disease (COPD) or acute lung injury. Our purpose was to design efficient carriers for lung delivery of small interfering RNA (siRNA) targeting tumor necrosis factor (TNF)alphain an acute lung injury model. To achieve this goal, two different types of phosphorus-based dendrimers with either pyrrolidinium or morpholinium as terminal protonated amino groups were selected for their better biocompatibility compared to other dendrimers. Dendriplexes containing pyrrolidinium surface groups demonstrated a stronger siRNA complexation, a higher cellular uptake and enhanced in vitro silencing efficiency of TNF-alpha in the lipopolysaccharide (LPS)-activated mouse macrophage cell line RAW264.7, compared to morpholinium-containing dendriplexes. The better performance of the pyrrolidium dendriplexes was attributed to their higher pKa value leading to a stronger siRNA complexation and improved protection against enzymatic degradation resulting in a higher cellular uptake. The superior silencing effect of the pyrrolidinium dendriplexes, compared to non-complexed siRNA, was confirmed in vivo in an LPS-induced murine model of short term acute lung injury upon lung delivery via nasal administration. These data suggest that phosphorous dendriplexes have a strong potential in lung delivery of siRNA for treating inflammatory lung diseases.
U2 - 10.1021/acs.biomac.7b00572
DO - 10.1021/acs.biomac.7b00572
M3 - Journal article
C2 - 28639789
VL - 18
SP - 2379
EP - 2388
JO - Biomacromolecules
JF - Biomacromolecules
SN - 1525-7797
IS - 8
ER -
ID: 179617356